Publications:

---

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

Current Oncology (Toronto, Ont.)

Spitaleri, Gianluca G; Trillo Aliaga, Pamela P; Attili, Ilaria I; Del Signore, Ester E; Corvaja, Carla C; Corti, Chiara C; Crimini, Edoardo E; Passaro, Antonio A; de Marinis, Filippo F

Publication Date: 2023-05-16

Variant appearance in text: ALK: I1171T

PubMed Link: 37232842

Variant Present in the following documents:

• Main text
• curroncol-30-00384.pdf

View BVdb publication page

---

Cerebrospinal fluid: A unique source of circulating tumor DNA with broad clinical applications.

Translational Oncology

Hickman, Richard A RA; Miller, Alexandra M AM; Arcila, Maria E ME

Publication Date: 2023-05-15

Variant appearance in text: ALK: I1171T

PubMed Link: 37196447

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

EML4-ALK biology and drug resistance in Non-Small Cell Lung Cancer: a new phase of discoveries.

Molecular Oncology

Elshatlawy, Mariam M; Sampson, Josephina J; Clarke, Katy K; Bayliss, Richard R

Publication Date: 2023-05-07

Variant appearance in text: ALK: I1171T

PubMed Link: 37149843

Variant Present in the following documents:

• Main text
• MOL2-17-950.pdf

View BVdb publication page

---

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

Nature Communications

Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP

Publication Date: 2023-05-05

Variant appearance in text: ALK: I1171T

PubMed Link: 37147298

Variant Present in the following documents:

• 41467_2023_38195_MOESM3_ESM.xlsx, sheet 1

View BVdb publication page

---

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.

Investigational New Drugs

Yang, Yingying Y; Zheng, Qingmei Q; Wang, Xinmei X; Zhao, Shuyong S; Huang, Wenshu W; Jia, Linchao L; Ma, Cuicui C; Liu, Shicong S; Zhang, Yongpeng Y; Xin, Qianqian Q; Sun, Yan Y; Zheng, Shansong S

Publication Date: 2023-04-10

Variant appearance in text: ALK: I1171T

PubMed Link: 37036582

Variant Present in the following documents:

• Main text
• 10637_2023_Article_1350.pdf

View BVdb publication page

---

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.

International Journal Of Molecular Sciences

Cheon, So Yeong SY; Kwon, Sunghark S

Publication Date: 2023-03-18

Variant appearance in text: ALK: I1171T

PubMed Link: 36982897

Variant Present in the following documents:

• Main text
• ijms-24-05821.pdf

View BVdb publication page

---

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.

International Journal Of Molecular Sciences

Wu, Jiajia J; Lin, Zhenghong Z

Publication Date: 2022-12-01

Variant appearance in text: ALK: I1171T

PubMed Link: 36499382

Variant Present in the following documents:

• Main text
• ijms-23-15056.pdf

View BVdb publication page

---

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation.

Frontiers In Endocrinology

He, Wenxin W; Cao, Xiankun X; Kong, Keyu K; Rong, Kewei K; Han, Shuai S; Qin, An A

Publication Date: 2022

Variant appearance in text: ALK: Ile1171Thr

PubMed Link: 36425467

Variant Present in the following documents:

• Main text
• fendo-13-939959.pdf

View BVdb publication page

---

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.

Frontiers In Oncology

Pasau, Thomas T; Wauters, Els E; Wauters, Isabelle I; Duplaquet, Fabrice F; Pirard, Lionel L; Pop-Stanciu, Claudia C; D'Haene, Nicky N; Dupont, Michael M; Vander Borght, Thierry T; Rondelet, Benoît B; Ocak, Sebahat S

Publication Date: 2022

Variant appearance in text: ALK: I1171T

PubMed Link: 36419902

Variant Present in the following documents:

• Main text
• fonc-12-985446.pdf

View BVdb publication page

---

Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review.

Frontiers In Oncology

Han, Dan D; Zhao, Kewei K; Yang, Qin Q; Zhang, Liling L; Fei, Shihong S

Publication Date: 2022

Variant appearance in text: ALK: I1171T

PubMed Link: 36324562

Variant Present in the following documents:

• Main text
• fonc-12-1016320.pdf

View BVdb publication page

---

Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives.

Cells

Guo, Haiyang H; Zhang, Jun J; Qin, Chao C; Yan, Hang H; Liu, Tao T; Hu, Haiyang H; Tang, Shengjie S; Tang, Shoujun S; Zhou, Haining H

Publication Date: 2022-10-12

Variant appearance in text: ALK: I1171T

PubMed Link: 36291069

Variant Present in the following documents:

• Main text

View BVdb publication page

---

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Cancers

Cognigni, Valeria V; Pecci, Federica F; Lupi, Alessio A; Pinterpe, Giada G; De Filippis, Chiara C; Felicetti, Cristiano C; Cantini, Luca L; Berardi, Rossana R

Publication Date: 2022-09-29

Variant appearance in text: ALK: I1171T

PubMed Link: 36230686

Variant Present in the following documents:

• Main text
• cancers-14-04765.pdf

View BVdb publication page

---

Molecular targeted therapy for anticancer treatment.

Experimental & Molecular Medicine

Min, Hye-Young HY; Lee, Ho-Young HY

Publication Date: 2022-10

Variant appearance in text: ALK: I1171T

PubMed Link: 36224343

Variant Present in the following documents:

• Main text
• 12276_2022_Article_864.pdf

View BVdb publication page

---

Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.

Bmc Cancer

Wu, Huita H; Ji, Haonan H; Yang, Wenhui W; Zhang, Min M; Guo, Yifang Y; Li, Bangkai B; Wang, Jiayin J; Chen, Rongrong R; Chen, Yuan Y; Wang, Xin X

Publication Date: 2022-09-27

Variant appearance in text: ALK: I1171T

PubMed Link: 36167530

Variant Present in the following documents:

• 12885_2022_9922_MOESM5_ESM.xlsx, sheet 1

View BVdb publication page

---

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.

Translational Cancer Research

Hu, Han H; Dai, Hui H; Ding, Liren L

Publication Date: 2022-08

Variant appearance in text: ALK: I1171T

PubMed Link: 36093526

Variant Present in the following documents:

• Main text
• tcr-11-08-2967.pdf

View BVdb publication page

---

Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer.

Diagnostics (Basel, Switzerland)

Pesta, Martin M; Shetti, Dattatrya D; Kulda, Vlastimil V; Knizkova, Tereza T; Houfkova, Katerina K; Bagheri, Mahyar Sharif MS; Svaton, Martin M; Polivka, Jiri J

Publication Date: 2022-07-25

Variant appearance in text: ALK: I1171T

PubMed Link: 35892510

Variant Present in the following documents:

• Main text
• diagnostics-12-01799.pdf

View BVdb publication page

---

AACR Project GENIE: 100,000 Cases and Beyond.

Cancer Discovery

Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,

Publication Date: 2022-09-02

Variant appearance in text: ALK: I1171T

PubMed Link: 35819403

Variant Present in the following documents:

• cd-21-1547_supplementary_table_1_suppst1.xlsx, sheet 1

View BVdb publication page

---

Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.

Frontiers In Oncology

Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J

Publication Date: 2022

Variant appearance in text: ALK: 3512T>C; I1171T

PubMed Link: 35814426

Variant Present in the following documents:

• DataSheet_1.xlsx, sheet 2

View BVdb publication page

---

The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation.

International Journal Of Molecular Sciences

Bearz, Alessandra A; De Carlo, Elisa E; Del Conte, Alessandro A; Spina, Michele M; Da Ros, Valentina V; Bertoli, Elisa E; Revelant, Alberto A; Stanzione, Brigida B; Tirelli, Umberto U

Publication Date: 2022-06-30

Variant appearance in text: ALK: I1171T

PubMed Link: 35806325

Variant Present in the following documents:

• Main text
• ijms-23-07322.pdf

View BVdb publication page

---

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).

Frontiers In Oncology

Raphael, Ari A; Onn, Amir A; Holtzman, Liran L; Dudnik, Julia J; Urban, Damien D; Kian, Waleed W; Cohen, Aharon Y AY; Moskovitz, Mor M; Zer, Alona A; Bar, Jair J; Rabinovich, Natalie Maimon NM; Grynberg, Shirly S; Oedegaard, Cecilie C; Agbarya, Abed A; Peled, Nir N; Shochat, Tzippy T; Dudnik, Elizabeth E

Publication Date: 2022

Variant appearance in text: ALK: I1171T

PubMed Link: 35646707

Variant Present in the following documents:

• Table_2.xlsx, sheet 1

View BVdb publication page

---

Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.

Thoracic Cancer

Nakagawa, Yoshiko Y; Shimizu, Tetsuo T; Hiranuma, Hisato H; Gon, Yasuhiro Y

Publication Date: 2022-05

Variant appearance in text: ALK: I1171T

PubMed Link: 35373538

Variant Present in the following documents:

• Main text
• TCA-13-1431.pdf

View BVdb publication page

---

Clinical and genomic features of Chinese lung cancer patients with germline mutations.

Nature Communications

Peng, Wenying W; Li, Bin B; Li, Jin J; Chang, Lianpeng L; Bai, Jing J; Yi, Yuting Y; Chen, Rongrong R; Zhang, Yanyan Y; Chen, Chen C; Pu, Xingxiang X; Jiang, Meilin M; Li, Jia J; Zhong, Rui R; Xu, Fang F; Chen, Bolin B; Xu, Li L; Wang, Ning N; Huan, Jiaojiao J; Dai, Pingping P; Guan, Yanfang Y; Yang, Ling L; Xia, Xuefeng X; Yi, Xin X; Wang, Jiayin J; Yu, Fenglei F; Wu, Lin L

Publication Date: 2022-03-10

Variant appearance in text: ALK: 3512T>C; I1171T

PubMed Link: 35273153

Variant Present in the following documents:

• 41467_2022_28840_MOESM7_ESM.xlsx, sheet 1

View BVdb publication page

---

Systematic review and meta-analysis of genomic alterations in acral melanoma.

Pigment Cell & Melanoma Research

Broit, Natasa N; Johansson, Peter A PA; Rodgers, Chloe B CB; Walpole, Sebastian T ST; Hayward, Nicholas K NK; Pritchard, Antonia L AL

Publication Date: 2022-05

Variant appearance in text: ALK: I1171T

PubMed Link: 35229492

Variant Present in the following documents:

• PCMR-35-369-s003.xlsx, sheet 12

View BVdb publication page

---

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.

Npj Precision Oncology

Yanagimura, Naohiro N; Takeuchi, Shinji S; Fukuda, Koji K; Arai, Sachiko S; Tanimoto, Azusa A; Nishiyama, Akihiro A; Ogo, Naohisa N; Takahashi, Hiroyuki H; Asai, Akira A; Watanabe, Satoshi S; Kikuchi, Toshiaki T; Yano, Seiji S

Publication Date: 2022-02-28

Variant appearance in text: ALK: I1171T

PubMed Link: 35228642

Variant Present in the following documents:

• Main text
• 41698_2022_Article_254.pdf

View BVdb publication page

---

Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?

Biochemical Society Transactions

Shevchenko, Ekaterina E; Pantsar, Tatu T

Publication Date: 2022-02-28

Variant appearance in text: ALK: I1171T

PubMed Link: 35226061

Variant Present in the following documents:

• Main text
• BST-50-633.pdf

View BVdb publication page

---

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Nature Cancer

Tamborero, David D; Dienstmann, Rodrigo R; Rachid, Maan Haj MH; Boekel, Jorrit J; Lopez-Fernandez, Adria A; Jonsson, Markus M; Razzak, Ali A; Braña, Irene I; De Petris, Luigi L; Yachnin, Jeffrey J; Baird, Richard D RD; Loriot, Yohann Y; Massard, Christophe C; Martin-Romano, Patricia P; Opdam, Frans F; Schlenk, Richard F RF; Vernieri, Claudio C; Masucci, Michele M; Villalobos, Xenia X; Chavarria, Elena E; , ; Balmaña, Judith J; Apolone, Giovanni G; Caldas, Carlos C; Bergh, Jonas J; Ernberg, Ingemar I; Fröhling, Stefan S; Garralda, Elena E; Karlsson, Claes C; Tabernero, Josep J; Voest, Emile E; Rodon, Jordi J; Lehtiö, Janne J

Publication Date: 2022-02

Variant appearance in text: ALK: Ile1171Thr

PubMed Link: 35221333

Variant Present in the following documents:

• 43018_2022_332_MOESM3_ESM.xlsx, sheet 1

View BVdb publication page

---

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.

Esmo Open

Hua, G G; Zhang, X X; Zhang, M M; Wang, Q Q; Chen, X X; Yu, R R; Bao, H H; Liu, J J; Wu, X X; Shao, Y Y; Liang, B B; Lu, K K

Publication Date: 2022-02-02

Variant appearance in text: ALK: I1171T

PubMed Link: 35123209

Variant Present in the following documents:

• main.pdf

View BVdb publication page

---

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.

Esmo Open

Hua, G G; Zhang, X X; Zhang, M M; Wang, Q Q; Chen, X X; Yu, R R; Bao, H H; Liu, J J; Wu, X X; Shao, Y Y; Liang, B B; Lu, K K

Publication Date: 2022-02

Variant appearance in text: ALK: I1171T

PubMed Link: 35123209

Variant Present in the following documents:

• main.pdf

View BVdb publication page

---

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.

Npj Precision Oncology

Tanimura, Keiko K; Yamada, Tadaaki T; Okada, Koutaroh K; Nakai, Kunihiro K; Horinaka, Mano M; Katayama, Yuki Y; Morimoto, Kenji K; Ogura, Yuri Y; Takeda, Takayuki T; Shiotsu, Shinsuke S; Ichikawa, Kosuke K; Watanabe, Satoshi S; Morimoto, Yoshie Y; Iwasaku, Masahiro M; Kaneko, Yoshiko Y; Uchino, Junji J; Taniguchi, Hirokazu H; Yoneda, Kazue K; Matoba, Satoaki S; Sakai, Toshiyuki T; Uehara, Hisanori H; Yano, Seiji S; Kusaba, Tetsuro T; Katayama, Ryohei R; Takayama, Koichi K

Publication Date: 2022-01-18

Variant appearance in text: ALK: I1171T

PubMed Link: 35042943

Variant Present in the following documents:

• Main text

View BVdb publication page

---

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.

Npj Precision Oncology

Tanimura, Keiko K; Yamada, Tadaaki T; Okada, Koutaroh K; Nakai, Kunihiro K; Horinaka, Mano M; Katayama, Yuki Y; Morimoto, Kenji K; Ogura, Yuri Y; Takeda, Takayuki T; Shiotsu, Shinsuke S; Ichikawa, Kosuke K; Watanabe, Satoshi S; Morimoto, Yoshie Y; Iwasaku, Masahiro M; Kaneko, Yoshiko Y; Uchino, Junji J; Taniguchi, Hirokazu H; Yoneda, Kazue K; Matoba, Satoaki S; Sakai, Toshiyuki T; Uehara, Hisanori H; Yano, Seiji S; Kusaba, Tetsuro T; Katayama, Ryohei R; Takayama, Koichi K

Publication Date: 2022-01-18

Variant appearance in text: ALK: I1171T

PubMed Link: 35042943

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.

Esmo Open

Wolf, J J; Helland, Å Å; Oh, I-J IJ; Migliorino, M R MR; Dziadziuszko, R R; Wrona, A A; de Castro, J J; Mazieres, J J; Griesinger, F F; Chlistalla, M M; Cardona, A A; Ruf, T T; Trunzer, K K; Smoljanovic, V V; Novello, S S

Publication Date: 2022-01-15

Variant appearance in text: ALK: I1171T

PubMed Link: 35042152

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.

Esmo Open

Wolf, J J; Helland, Å Å; Oh, I-J IJ; Migliorino, M R MR; Dziadziuszko, R R; Wrona, A A; de Castro, J J; Mazieres, J J; Griesinger, F F; Chlistalla, M M; Cardona, A A; Ruf, T T; Trunzer, K K; Smoljanovic, V V; Novello, S S

Publication Date: 2022-02

Variant appearance in text: ALK: I1171T

PubMed Link: 35042152

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.

Frontiers In Cell And Developmental Biology

Liang, Shuai S; Wang, Qing Q; Qi, Xuesen X; Liu, Yudi Y; Li, Guozhen G; Lu, Shaoyong S; Mou, Linkai L; Chen, Xiangyu X

Publication Date: 2021

Variant appearance in text: ALK: I1171T

PubMed Link: 35004700

Variant Present in the following documents:

• Main text

View BVdb publication page

---

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.

Cancer Cell International

Fernandes, Maria Gabriela O MGO; Cruz-Martins, Natália N; Machado, José Carlos JC; Costa, José Luís JL; Hespanhol, Venceslau V

Publication Date: 2021-12-16

Variant appearance in text: ALK: I1171T

PubMed Link: 34915883

Variant Present in the following documents:

• Main text
• 12935_2021_Article_2382.pdf

View BVdb publication page

---

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.

Cancer Cell International

Fernandes, Maria Gabriela O MGO; Cruz-Martins, Natália N; Machado, José Carlos JC; Costa, José Luís JL; Hespanhol, Venceslau V

Publication Date: 2021-12-16

Variant appearance in text: ALK: I1171T

PubMed Link: 34915883

Variant Present in the following documents:

• Main text
• 12935_2021_Article_2382.pdf

View BVdb publication page

---

Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Molecules (Basel, Switzerland)

Musumeci, Francesca F; Cianciusi, Annarita A; D'Agostino, Ilaria I; Grossi, Giancarlo G; Carbone, Anna A; Schenone, Silvia S

Publication Date: 2021-11-23

Variant appearance in text: ALK: I1171T

PubMed Link: 34885651

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Molecules (Basel, Switzerland)

Musumeci, Francesca F; Cianciusi, Annarita A; D'Agostino, Ilaria I; Grossi, Giancarlo G; Carbone, Anna A; Schenone, Silvia S

Publication Date: 2021-11-23

Variant appearance in text: ALK: I1171T

PubMed Link: 34885651

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: I1171T

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: I1171T

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.

Embo Molecular Medicine

Lu, Yue Y; Fan, Zhenzhen Z; Zhu, Su-Jie SJ; Huang, Xiaoxing X; Zhuang, Zhongji Z; Li, Yunzhan Y; Deng, Zhou Z; Gao, Lei L; Hong, Xuehui X; Zhang, Ting T; Li, Li L; Sun, Xihuan X; Huang, Wei W; Zhang, Jingfang J; Liu, Yan Y; Zhang, Baoding B; Jiang, Jie J; Gui, Fu F; Wang, Zheng Z; Li, Qiyuan Q; Song, Siyang S; Huang, Xin X; Wu, Qiao Q; Chen, Lanfen L; Zhou, Dawang D; Zhang, Jianming J; Yun, Cai-Hong CH; Chen, Liang L; Deng, Xianming X

Publication Date: 2022-01-11

Variant appearance in text: ALK: I1171T

PubMed Link: 34845836

Variant Present in the following documents:

• Main text

View BVdb publication page

---

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.

Embo Molecular Medicine

Lu, Yue Y; Fan, Zhenzhen Z; Zhu, Su-Jie SJ; Huang, Xiaoxing X; Zhuang, Zhongji Z; Li, Yunzhan Y; Deng, Zhou Z; Gao, Lei L; Hong, Xuehui X; Zhang, Ting T; Li, Li L; Sun, Xihuan X; Huang, Wei W; Zhang, Jingfang J; Liu, Yan Y; Zhang, Baoding B; Jiang, Jie J; Gui, Fu F; Wang, Zheng Z; Li, Qiyuan Q; Song, Siyang S; Huang, Xin X; Wu, Qiao Q; Chen, Lanfen L; Zhou, Dawang D; Zhang, Jianming J; Yun, Cai-Hong CH; Chen, Liang L; Deng, Xianming X

Publication Date: 2021-11-30

Variant appearance in text: ALK: I1171T

PubMed Link: 34845836

Variant Present in the following documents:

• Main text

View BVdb publication page

---

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.

Nature Communications

Szydzik, Joanna J; Lind, Dan E DE; Arefin, Badrul B; Kurhe, Yeshwant Y; Umapathy, Ganesh G; Siaw, Joachim Tetteh JT; Claeys, Arne A; Gabre, Jonatan L JL; Van den Eynden, Jimmy J; Hallberg, Bengt B; Palmer, Ruth H RH

Publication Date: 2021-11-24

Variant appearance in text: ALK: I1171T

PubMed Link: 34819497

Variant Present in the following documents:

• 41467_2021_Article_27057.pdf

View BVdb publication page

---

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why?

International Journal Of Molecular Sciences

Kaczmarska, Agnieszka A; Śliwa, Patrycja P; Lejman, Monika M; Zawitkowska, Joanna J

Publication Date: 2021-11-08

Variant appearance in text: ALK: I1171T

PubMed Link: 34769519

Variant Present in the following documents:

• Main text
• ijms-22-12089.pdf

View BVdb publication page

---

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.

Cancers

Villa, Matteo M; Sharma, Geeta G GG; Manfroni, Chiara C; Cortinovis, Diego D; Mologni, Luca L

Publication Date: 2021-10-14

Variant appearance in text: ALK: I1171T

PubMed Link: 34680298

Variant Present in the following documents:

• Main text

View BVdb publication page

---

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers In Oncology

Pan, Yue Y; Deng, Chao C; Qiu, Zhenhua Z; Cao, Chenghui C; Wu, Fang F

Publication Date: 2021

Variant appearance in text: ALK: I1171T

PubMed Link: 34660278

Variant Present in the following documents:

• Main text
• fonc-11-713530.pdf

View BVdb publication page

---

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology

Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C

Publication Date: 2021

Variant appearance in text: ALK: I1171T

PubMed Link: 34630336

Variant Present in the following documents:

• Table_1.xlsx, sheet 2

View BVdb publication page

---

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.

Jto Clinical And Research Reports

Zhu, Viola W VW; Nagasaka, Misako M; Madison, Russell R; Schrock, Alexa B AB; Cui, Jean J; Ou, Sai-Hong Ignatius SI

Publication Date: 2021-01

Variant appearance in text: ALK: I1171T

PubMed Link: 34589977

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma-A Comprehensive Update.

Pharmaceutics

Brenner, Annette K AK; Gunnes, Maria W MW

Publication Date: 2021-09-08

Variant appearance in text: ALK: I1171T

PubMed Link: 34575503

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas.

Journal Of Oncology

Liu, Zhichao Z; Li, Changchun C

Publication Date: 2021

Variant appearance in text: ALK: I1171T

PubMed Link: 34557229

Variant Present in the following documents:

• JO2021-1615201.pdf

View BVdb publication page

---

A narrative review of tumor heterogeneity and challenges to tumor drug therapy.

Annals Of Translational Medicine

Zhu, Liang L; Jiang, Minlin M; Wang, Hao H; Sun, Hui H; Zhu, Jun J; Zhao, Wencheng W; Fang, Qiyu Q; Yu, Jia J; Chen, Peixin P; Wu, Shengyu S; Zheng, Zixuan Z; He, Yayi Y

Publication Date: 2021-08

Variant appearance in text: ALK: I1171T

PubMed Link: 34532488

Variant Present in the following documents:

• Main text
• atm-09-16-1351.pdf

View BVdb publication page

---

Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.

Biomedicines

Palacín-Aliana, Irina I; García-Romero, Noemí N; Asensi-Puig, Adrià A; Carrión-Navarro, Josefa J; González-Rumayor, Víctor V; Ayuso-Sacido, Ángel Á

Publication Date: 2021-07-28

Variant appearance in text: ALK: I1171T

PubMed Link: 34440110

Variant Present in the following documents:

• Main text
• biomedicines-09-00906.pdf

View BVdb publication page

---

Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.

Cancer Science

Hasegawa, Nobuhiko N; Kohsaka, Shinji S; Kurokawa, Kana K; Shinno, Yuki Y; Takeda Nakamura, Ikuko I; Ueno, Toshihide T; Kojima, Shinya S; Kawazu, Masahito M; Suehara, Yoshiyuki Y; Ishijima, Muneaki M; Goto, Yasushi Y; Kojima, Yuki Y; Yonemori, Kan K; Hayashi, Takuo T; Saito, Tsuyoshi T; Shukuya, Takehito T; Takahashi, Fumiyuki F; Takahashi, Kazuhisa K; Mano, Hiroyuki H

Publication Date: 2021-10

Variant appearance in text: ALK: I1171T

PubMed Link: 34310819

Variant Present in the following documents:

• Main text

View BVdb publication page

---

One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.

The Oncologist

Lee, Youngjoo Y; Cho, Youngnam Y; Park, Eun Young EY; Park, Seong-Yun SY; Hwang, Kum Hui KH; Han, Ji-Youn JY

Publication Date: 2021-10

Variant appearance in text: ALK: I1171T

PubMed Link: 34272914

Variant Present in the following documents:

• ONCO-26-e1683-s002.pdf

View BVdb publication page

---

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.

Cold Spring Harbor Molecular Case Studies

Liu, Tingting T; Merguerian, Matthew D MD; Rowe, Steven P SP; Pratilas, Christine A CA; Chen, Allen R AR; Ladle, Brian H BH

Publication Date: 2021-08

Variant appearance in text: ALK: I1171T

PubMed Link: 34210658

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.

Thoracic Cancer

Kobayashi, Takashi T; Kanda, Shintaro S; Fukushima, Toshirou T; Noguchi, Takuro T; Sekiguchi, Nodoka N; Koizumi, Tomonobu T

Publication Date: 2021-08

Variant appearance in text: ALK: I1171T

PubMed Link: 34184417

Variant Present in the following documents:

• Main text

View BVdb publication page

---